We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

No False Positives with New Enterovirus D68 PCR-Based Assay

By LabMedica International staff writers
Posted on 16 Aug 2015
Print article
Image: Electron micrograph of a thin section of EV-D68, showing the numerous, spherical viral particles (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
Image: Electron micrograph of a thin section of EV-D68, showing the numerous, spherical viral particles (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
A newly developed PCR-based assay specifically detects current variants of Enterovirus D68 with no false positive reactions with other enteroviruses or with rhinoviruses.

Investigators at Washington University School of Medicine (St. Louis, MO, USA) used an Applied Biosystems (Foster City, CA, USA) 7500 real-time PCR system to develop and evaluate a real-time reverse transcriptase PCR (RT-PCR) assay for the detection of human Enterovirus D68 (EV-D68) in clinical specimens. This assay was developed in response to the unprecedented 2014 nationwide EV-D68 outbreak in the United States associated with severe respiratory illness.

The investigators mapped the genome sequence of the EV-D68 virus circulating in St. Louis (MO, USA). This sequence, along with other GenBank sequences from past EV-D68 occurrences, was used to computationally select a region of EV-D68 appropriate for targeting in a strain-specific RT-PCR assay. The RT-PCR assay amplified a segment of the VP1 gene, with an analytic limit of detection of four copies per reaction, and it was more sensitive than commercially available assays that detect enteroviruses and rhinoviruses without distinguishing between the two, including three multiplex respiratory panels approved for clinical use by the [US] Food and Drug Administration. The new assay did not detect any other enteroviruses or rhinoviruses tested and did detect divergent strains of EV-D68,

"Commercial tests for respiratory viral infections typically do not distinguish between rhinoviruses, which cause the common cold, and enteroviruses, and within each of those groups there are many different types," said senior author Dr. Gregory A. Storch, professor of pediatrics at Washington University School of Medicine. "Having a tool to identify which cases of respiratory illness are actually EV-D68 is an advantage for public health. These kinds of tests help treatment decisions because it is important to know that the patient does not have influenza or another disease that might require a specific treatment. It is also important in a hospital for preventing infections because doctors take patients with one particular virus and keep them apart from patients infected with other infectious agents."

"There are a range of D68 viruses, and our assay was designed to detect them all," said Dr. Storch. "We received many samples of enterovirus from other hospitals and ran the test blindly on all of them. In the viruses we looked at, the test worked 100% of the time. It only detected EV-D68 strains, and it did detect all of them; the test did not detect any of the other enteroviruses or rhinoviruses."

Details of the EV-D68 assay were published in the June 10, 2015, online edition of the Journal of Clinical Microbiology.

Related Links:
Washington University School of Medicine
Applied Biosystems


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.